Prognostic relevance of AGO2 expression in adrenocortical carcinoma (ACC): associations with clinicopathological features

Background: Adrenocortical carcinoma (ACC) is an aggressive malignancy with high recurrence rate, even after complete surgical resection. Currently biomarkers are limited in their ability to assist diagnosis or prognostication.1 While secretion of cortisol and androgens is associated with poorer outcomes,2 biomarkers with greater prognostic accuracy would be desirable. AGO2, a key regulator of miRNA function, plays a significant role in tumour biology.3 This study evaluated AGO2’s prognostic potential in ACC by correlating its expression with clinicopathological features, including hormone status, and overall survival.